Clinical trial
Docetaxel and Oxaliplatin in Gastric Cancer
NCT00382720 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00382720 |
|---|---|
| Title | Docetaxel and Oxaliplatin in Gastric Cancer |
| Official title | A Randomized Phase II Study of Docetaxel in Combination With Oxaliplatin With or Without 5-FU or Capecitabine in Metastatic or Locally Recurrent Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stomach Neoplasms |
| Intervention type | Drug |
| Interventions | Docetaxel + Oxaliplatin, Docetaxel + Oxaliplatin + 5-FU, Docetaxel + Oxaliplatin + Capecitabine |
| Enrollment | 275 |
| Start date | Sep 1, 2006 |
| Primary completion | Apr 1, 2010 |
| Completion | Apr 1, 2010 |
| First posted | Sep 29, 2006 |
| Last update posted | Jan 7, 2013 |
| Countries | Belgium, France, Germany, Hungary, Italy, Portugal, Russia, Spain, Switzerland, Turkey (Türkiye), United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: